Data Suggest Biaxin(R) XL (Clarithromycin Extended-Release Tablets) May Have Less-Severe Gastrointestinal Side Effects Than Augmentin(R) (Amoxicillin/Clavulanate)Biaxin XL for Seven Days and Augmentin for 10 days Showed Similar Results in a Study for the Treatment of Acute Exacerbation of Chronic Bronchitis
ABBOTT PARK, Ill., Oct. 25 /PRNewswire/ -- Data from a study presented today at the annual meeting of the American College of Chest Physicians shows patients treated for acute bacterial exacerbation of chronic bronchitis (AECB) with
once-daily Biaxin® XL (clarithromycin extended-release tablets) for seven days experienced significantly less-severe gastrointestinal (GI) side effects than those taking another leading antibiotic, Augmentin® (amoxicillin/clavulanate), for 10 days.
In this study, which was designed to compare the safety and efficacy of the two medications, the treatments were equally
effective in treating AECB. Overall incidence of treatment-related adverse events was shown to be similar, with a significant difference in abnormal taste reported by more patients taking Biaxin XL. In addition, significantly more patients taking Biaxin XL gave a response of ``excellent'' or ``very good'' when asked, ``How do you feel today?'' at study days 10-12 than those taking Augmentin.
``These data regarding the tolerability of Biaxin XL are consistent with previous studies that show Biaxin XL is a well-tolerated treatment option,'' said Antonio Anzueto, M.D., associate professor of medicine, Division of Pulmonary Disease/Critical Care Medicine, University of Texas Health Science Center at San Antonio. ``In addition, Biaxin XL offers patients the convenience of once-a-day dosing in a shorter course of therapy.''
Biaxin XL is a once-daily formulation of Abbott laboratories' (NYSE: ABT - news) widely prescribed advanced-generation macrolide antibiotic, Biaxin® (clarithromycin) tablets, and was approved by the U.S. Food and Drug Administration (FDA) in March 2000 for mild to moderate infections in adults for the treatment of acute maxillary sinusitis (AMS) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae and acute bacterial exacerbation of chronic bronchitis (AECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. The efficacy and safety of Biaxin XL in treating other infections for which other formulations of Biaxin are
approved have not been established. In adult clinical trials in both AMS and AECB, Biaxin XL tablets taken once daily resulted in clinical cure rates comparable to those of the immediate-release formulation, Biaxin tablets, taken twice daily.
things continuing to improve here.
chris |
